Once a corneal scar develops, surgical management remains the only option for visual rehabilitation. Corneal transplantation is the definitive treatment for a corneal scar. In addition to the challenges posed by graft rejections and other postoperative complications, the lack of high-quality donor corneas can limit the benefits possible with keratoplasty. The purpose of our study was to evaluate a new therapeutic strategy for treating corneal scarring by targeting collagen deposition. We overexpressed a fibril collagenase (matrix metalloproteinase 14 (MMP14)) to prevent collagen deposition in the scar tissue. We demonstrated that a single and simple direct injection of recombinant adeno-associated virus-based vector expressing murine MMP14 can modulate gene expression of murine stromal keratocytes. This tool opens new possibilities with regard to treatment. In a mouse model of corneal full-thickness incision, we observed that MMP14 overexpression reduced corneal opacity and expression of the major genes involved in corneal scarring, especially type III collagen and a-smooth muscle actin. These results represent proof of concept that gene transfer of MMP14 can reduce scar formation, which could have therapeutic applications after corneal trauma.
INTRODUCTION
Understanding the mechanisms of corneal wound healing and why this process so often results in scarring remains a major challenge for clinicians and researchers. A worrying consequence of this situation is the lack of efficient therapies to treat the condition or prevent scarring, which in the most severe cases can lead to corneal blindness. Treatment of corneal blindness depends on the underlying disease or condition. Once a corneal scar develops, surgical management remains the only option for visual rehabilitation. Corneal transplantation is the definitive treatment for corneal scars. In addition to graft rejections and other postoperative complications, the lack of high-quality donor corneas can limit the benefits that should be possible with keratoplasty. Several treatments have been proposed to treat scarring in order to avoid corneal transplantation. These include topical application of steroids, 1 cell cycle inhibitors (mitomycine-C), 2 human amniotic membrane, 3 urokinase plasminogen activator 4 and interferon a2b, 5 as well as attempts to modulate the level of active growth factors, especially transforming growth factor-b, to reduce the number of activated cells in the corneal stroma (for example, myofibroblasts) producing an excess of extracellular matrix. 6 To date, the results have been quite disappointing and the tested compounds are either ineffective or accompanied by various side effects. Another limitation is that none of these previous attempts have specifically targeted the major underlying biological phenomenon-the disorganization and excess accumulation of connective tissue. Consequently, the only effective treatment for corneal scarring is corneal transplantation, despite its limitations.
Corneal wound healing is a complex process that relies on the interplay of proteases and their inhibitors for proper extracellular matrix remodeling. Metalloproteinases have a major role in extracellular matrix remodeling during wound healing. 7 Extracellular matrix proteases tightly coordinate the balance of extracellular matrix synthesis, degradation and remodeling. Disorders occur when there is an imbalance between proteases and protease inhibitors. When the balance is in favor of the proteases, it causes pathologic degradation of stromal collagen and proteoglycans in the cornea. This could in the end induce corneal ulcers. 8 If the balance favors the inhibitors, extracellular matrix accumulates and fibrosis takes place. Such conditions result in permanent corneal opacity. 9 The composition of this matrix is very different from that of the normal, uninjured stroma, and is mainly formed by fibrillar type III collagen. This difference in composition, as well as the disorganized manner of repair-related tissue deposition, contributes to corneal opacity. 10 Matrix metalloproteinases (MMPs) are a group of zinc-binding proteolytic enzymes that participate in degrading and remodeling of the extracellular matrix in various physiological and pathologic conditions, including tumor progression and metastasis, inflammatory diseases and wound healing. 11, 12 These enzymes are classified in groups associated with their substrate specificity and structural biology. The collagenases, gelatinases, stromelysins, matrilysins, membrane-type MMP and others generally consist of a prodomain, a catalytic domain, a hinge region and a hemopexin domain. Notably, these enzymes can be secreted from the cell or anchored at the cell surface. MMP are specifically regulated at many levels.
Previous works showed that several MMP are expressed during corneal wound healing. 8 MMP 2, 3, 7, 9, 12 and 13 have been identified in migrating epithelial cells, stromal keratocytes and inflammatory cells. 7, [13] [14] [15] [16] [17] [18] MMP14 expression was strongly induced in basal epithelial cells in the initial days after corneal wounding, appearing later in keratocytes. 17 It has been suggested that MMP14 has a role in stromal extracellular matrix remodeling 17 but no report thus far has attempted to modulate its expression in vivo. Our hypothesis is that overexpression of MMP14 by stromal cells will target type III collagen deposition in the scar tissue, and thus will lead the corneal cells to restore the extracellular matrix to a level that allows transparency.
RESULTS
Gene transfer in the unwounded corneal stroma AAV2/8. gfp and AAV2/8.mmp14 vectors: dose-response experiments. We sought to determine the optimal dose of vector genome that would provide the best transgene expression with no side effects. For the first dose of 2.10e 10 vector genome (vg) per cornea, green fluorescent protein (GFP) fluorescence was visible as early as D7 and as late as D56 (Figure 1 ). Moreover, we observed neither inflammation nor corneal opacity for the AAV2/8.gfp vector up to 56 days after injection. With regard to the AAV2/8.mmp14 vector, small-grade opacities and a few neovessels were observed at D7 (not shown). At day 21 (Table 1) , all the mice presented light to severe opacities and almost half of them had neovessels inside the cornea. Slit-lamp observation depicted thin stroma, and three mice exhibited corneas that were dangerously close to perforation. As these observations were not consistent with our research goal, we decided not to pursue this line of experimentation.
We then decided to dilute the vector dose and injected ten and five times fewer viral particles (that is, 2.10e 9 and 4.10e 9 vg per cornea). We observed limited opacity in very few mice, but did not observe any stromal thinning or neovessel formation. These mice were followed for up to 8 months; at this time all the corneas were totally clear ( Table 2) . Considering these preliminary results, AAV2/8.gfp was considered as a suitable control vector, and we decided to use a dose of 4.10e 9 vg per cornea for the next steps of our study.
In the next step, we ensured that our transgene was properly expressed in normal corneas. We showed that recombinant MMP14 (rMMP14) mRNA was detectable as early as D7 post injection. The mRNA expression increased from D7 to D14 (Figure 2a) post injection, which correlated with an increase in levels of MMP14 mRNA and protein in AAV2/8.mmp14-transduced corneas as compared with those from AAV2/8.gfp-treated mice or non-transduced mice (Figures 2a, b, c and d) .
Effect of MMP14 overexpression on corneal repair Clinical and histological evaluation. In this study, 4.10e 9 vg per cornea of AAV2/8.gfp or AAV2/8.mmp14 was injected 10 h before the wound-healing assay. Corneal opacities were scored 14 days later. We observed a significant difference in opacity scoring between the AAV2/8.mmp14-treated mice and the AAV2/8.gfp-treated mice. Clinically, this treatment reduced the extent of scarring in the AAV2/8. mmp14-treated mice. As shown in Table 3 , there were significantly fewer cases of severe scarring and more cases of transparent corneas in the AAV2/8.mmp14-treated group. The results in the grade 1 and grade 2 columns confirm this tendency. This difference was statistically significant (Po0.01).
We presented the different types of opacities visualized by biomicroscopy in this wound-healing assay ( Figure 3a) . As pictured in Figures 3b and c, histological differences were linked to the overall severity of the opacity. Histopathological analysis did not show significant differences between the two groups when each parameter (neovascularization, edema, corneal thickness, neutrophil infiltration, fibroplasia and a-smooth muscle actin (a-SMA) expression) was analyzed separately. Principal component analysis showed that unlike the AAV2/8.gfp group, corneal thickness and edema were independent phenomena in AAV2/8.mmp14-treated mice ( Figure 4 , correlation factor À0.14). All the other parameters (edema, a-SMA, neovascularization, neutrophils and fibroplasia) were linked. This highlights the putative effect of MMP14 activity. Moreover, we observed elevated mRNA expression of gene markers associated with scarring. However, the magnitude of this increase was reduced in the AAV2/8.mmp14-treated mice as compared with the AAV2/8.gfp group, with significant differences for type III collagen, a-SMA and MMP2 (Table 4) . However, MMP14 mRNA expression was greater in the AAV2/8.mmp14-treated group (Po0.05). For type I collagen, we only noticed a non-significant difference in its expression between the control and the AAV2/8.mmp14-treated groups.
DISCUSSION
The purpose of our study was to evaluate a new therapeutic strategy approach to treating corneal scarring that targets collagen deposition. We overexpressed a fibril collagenase (that is MMP14) to prevent collagen deposition. We showed that a single and simple direct injection of recombinant adeno-associated virus-based vector expressing the murine MMP14 can modulate gene expression of stromal keratocytes. Thus, this tool suggests potential avenues to explore novel therapeutic treatments. In a mouse model of corneal full-thickness incision, we observed that MMP14 overexpression reduced corneal opacity and the level of expression of the major genes involved in corneal scarring, especially type III collagen and a-SMA.
Up to now, few studies have reported efficient transduction of keratocytes. Saika et al. 19 used an adenovirus encoding peroxisome proliferator-activated receptor-g, which was applied on the ocular surface of alkali-burned mouse cornea. They obtained interesting results in the context of a chemical burn, observing transient expression of their transgene in both the epithelium and the stroma. Bemelmans et al. demonstrated efficient lentiviral gene transfer in the corneal stroma cells using a femtosecond laser. 20 They obtained promising results, but the use of both lentivirus and femtosecond laser could limit the clinical applications of this technique. 21 Overexpression of rMMP14 was achieved using an adenoassociated viral vector carrying MMP14 complementary DNA under the control of the cytomegalovirus (CMV) promoter. The preliminary experiments using AAV2/8.CMV.gfp demonstrated a high rate of keratocyte transfection in unwounded cornea. GFP expression was observed at 7 days after transfection. The timeline was similar for rMMP14 mRNA expression in mice with unwounded corneas, and the level of rMMP14 mRNA expression was similar to that observed in other cell types. 22 Because of this delayed expression and because injecting a previously incised mouse cornea is technically impossible, we decided to administer the vector and then perform cornea fullthickness incision 10 h later. This approach allowed us to specifically transfect keratocytes, as demonstrated by the specificity obtained with GFP transfection: there was no epithelial diffusion while the basement membrane was intact. Because of the small delay between transfection and effective expression of the transgene, our clinical target is the early phase of corneal wounding, before an opaque corneal scar forms (in conditions wherein such scars are expected). The biological effects of MMP14 are multiple and complex. MMP14 is a fibrillar collagenase 23, 24 and as such is able to degrade the type III collagen present in scar tissue. Our initial strategy involved removal of the scar tissue rich in type III collagene, by proteolysis via MMP14. Preliminary experiments with high doses of AAV2/8.mmp14 vector demonstrated the collagenase ability of our construct, as we observed stromal melting and perforation. At the working dose, we did not observe such phenomena. Histopathology was relatively similar between the control group and the AAV2/8.mmp14-treated mice with regard to several parameters (edema, corneal thickness, neovascularization, neutrophils, fibroplasia and myofibroblast detection). However, statistical analysis highlighted the gene transfer effect: in the AAV2/8.mmp14 group, corneal thickness was not linked to edema as it was in the AAV2/8.gfp group, suggesting collagenase activity.
There is no direct link between MMP14 overexpression and the level of expression of the proteins we investigated. Although MMP14 overexpression can reduce corneal opacity, its role in major genes involved in corneal scarring was surprising. Our hypothesis is that a feedback loop is activated. MMP14-induced extracellular matrix remodeling may affect myofibroblasts. This hypothesis is in accordance with a recent paper by Hinz et al. 25 in a review dedicated to myofibroblast. Grinnell et al. reported that, in vitro, decreased stiffness of the extracellular matrix due to collagen relaxation inhibited myofibroblasts. 26 A similar mechanism could occur in vivo, with decreased extracellular matrix tension induced by the degradation of type III collagen by MMP14. Although the outcome of the myofibroblasts (that is, apoptosis or undifferentiation to a less active state) was unclear, remodeling of the extracellular matrix might have reduced internal stiffness resulting in a decrease of myofibroblasts. This hypothesis might explain the decreases in a-SMA and type III collagen mRNA. We observed no upregulation of type I collagen mRNA, which implied the absence of adverse effects on this collagen, which is the main component of the normal corneal stromal extracellular matrix.
MMP14 has been described as a mediator of angiogenesis with contrasting effects. [27] [28] [29] MMP14 can act in a proangiogenic capacity by degrading extracellular matrix components and favoring endothelial cell migration. However, it can also release antiangiogenic peptides from extracellular matrix proteins, such as endostatin. Azar and coworkers. 27, 30 reported that corneal injection of complementary DNA plasmid encoding MMP14 induced angiogenesis and that MMP14 colocalized with VEGF. They also demonstrated that the angiogenic effect of MMP14 could be mediated by proteolysis of decorin and collagen XVIII. 30 During preliminary experiments, we observed that high quantities of vector particles of AAV2/8.mmp14 induced angiogenesis, as well as stromal perforation, in unwounded cornea. However, using a lower titer of vector did not induce angiogenesis or stromal melting. As stated in a recent paper and review, 30,31 these results are not contradictory and reflect the complexity of angiogenesis, whether in physiological or pathological conditions. In our wound-healing model, the degree of neovascularization depends on the general state of the cornea, but no difference between the control group and the AAV2/ 8.mmp14 group was observed. Those results indicate that potential detrimental effects of corneal neovascularization were not induced by MMP14 expression in our model, and the results highlight the benefit of working with a low level of MMP14 expression. Prevention of scar tissue formation is an important clinical consideration after corneal injury. The targeted modulation of corneal wound healing, before a stationary scar appears, could have considerable clinical relevance. In the present study, using a full-thickness punched cornea murine wound-healing model, we present the proof of concept that gene transfer of MMP14 can reduce scar formation, which could have therapeutic applications after corneal trauma. In future investigations, we will use the same strategy in established scars, in an attempt to eliminate corneal opacity. This could provide a new therapeutic alternative for the treatment of corneal blindness that avoids corneal grafting and its potential complications. Finally, due to the broad similarity of the wound-healing response in different tissues, such an approach could be of interest in the treatment of several other fibrotic disorders.
MATERIALS AND METHODS

Animals and the corneal scarring model
C57BL/6 female mice aged from 12 to 16 weeks were used in this study. All procedures in animals were performed in accordance with the tenets of the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals and approved by the Research Unit Animal Care Ethics Committee.
Anesthesia was performed by intraperitoneal injection of 20 mg kg À1 ketamine hydrochloride (Panpharma, Fougères, France) and 8.8 mg kg À1 xylazine hydrochloride (Bayer Healthcare, Loos, France). Before surgery, atropine sulfate 1% ophthalmic solution (Alcon Laboratories Inc., Fort Worth, TX, USA) as well as 0.4% oxybuprocaine (Novartis Pharma Schweiz AG, Bern, Switzerland) were applied topically. Euthanasia was performed after inhalation of isoflurane, followed by dislocation of cervical vertebrae. All corneal surgeries were performed by the same surgeon to ensure consistency across specimens.
The murine full-thickness incision model was adapted from the penetrating keratectomy model described by Stramer et al. 10 Briefly, a 0.75 mm fullthickness button of central cornea tissue including all three corneal tissue layers (epithelium, stroma and endothelium) was ablated. A 26-gauge needle was used to mark the area that was then removed with microdissecting scissors. This model allows fibrotic repair with differentiation of keratocytes into myofibroblasts (expression of a-SMA).
In preliminary experiments, we investigated several time points after wounding (D7, D14, D21 and D28). We finally focused on D14, as at this stage, corneal opacity was maximal.
Clinical grading of corneal opacity
The level of opacity in the cornea was measured with a slit-lamp every week after wounding, using a method previously described. 32 Grade 0 was used to describe a completely clear cornea or one with trace opacity obliquely illuminated with slit-lamp biomicroscopy; grade 1 denoted more prominent opacity that did not interfere with the visualization of fine iris details; grade 2 denoted moderate obscuration of the iris and lens; and grade 3 denoted complete opacification of the stroma in the area of the ablation. Opacity grading was performed in a masked manner by two independent ophthalmologists trained in corneal examination.
Sample collection
For histology, eyes were collected and fixed with buffered 4% formaldehyde (LaboNord, Templemars, France) for 24 h, then rinsed with ethanol 70%, dehydrated and paraffin-embedded.
For immunohistochemistry, we used the periodate-lysine-paraformaldehyde technique described by Brenes et al. 33 Briefly, eyes were collected and fixed in periodate-lysine-paraformaldehyde solution for 3 h, then rinsed with physiological serum, dehydrated and paraffin-embedded. For RNA analysis, corneas were excised from the eyes. Careful dissection of the stromal tissue was performed with microsurgery scissors. The entire corneal epithelium was then mechanically removed by gentle scraping with a scalpel. Samples were then flash-frozen into liquid nitrogen until further use.
Histopathology
Histopathology was performed on samples collected 14 days after wounding. Corneal cross sections that were 3 mm thick were cut, deparaffinized and rehydrated in phosphate-buffered saline. Histological analysis (hematoxylin and eosin staining, Masson trichrome staining) was then conducted to evaluate neovascularization, edema, corneal thickness, neutrophil infiltration, fibroplasia and myofibroblast infiltration. Each parameter was scored from 0 to 3 using the following evaluation criterion. Neovascularization: microscopic observation of vascular spaces lined by flattened endothelial cells (neo-vessels) often containing red blood cells, in the corneal stroma, which was best evidenced by Masson trichrome staining. The number (density) and size of the vascular spaces were evaluated: grade 1, absence of neovessels; grade 2, some neovessels; and grade 3, numerous or large sized vessels. Edema: the histological appearance of stromal edema was characterized by a 'washed out' appearance of the corneal lamellae, which was best evidenced by Masson trichrome staining. The severity and extension of edema were graded using a three-step scale: grade 1, absent; grade 2, slight to moderate; and grade 3, severe. Corneal thickness: evaluated by comparison with controls in which grade 1, thinned cornea; grade 2, normal corneal thickness; and grade 3, increased corneal thickness. Neutrophils infiltration: observation of neutrophilic granulocytes in the corneal stroma in and around the lesions: grade 1, absence of neutrophils; grade 2, some neutrophils; and grade 3, numerous neutrophils. Fibroplasia: evaluation of the activation and proliferation of keratocytes (and myofibroblasts) in stromal healing: grade 1, slight and focal; grade 2, moderate; and grade 3, severe. Myofibroblasts: number and extension of the a-SMA-labeled (brown staining) cells in the corneal stroma. Group to group statistical analysis was then performed for each parameter (see statistical analysis section).
Production of AAV2/8.mmp14 vector Plasmid SSV9.CMV.mmp14, used for the production of AAV2/8.mmp14, consists of the AAV2 inverted terminal repeats, between which lies the coding sequence for the murine recombinant MMP14 (rMMP14) complementary DNA flanked by the CMV promoter and the simian virus 40 polyadenylation signal. The AAV2/8.mmp14 vector was produced as described earlier 34 in the Vector Core at the University Hospital of Nantes (http://www.vectors.nantes. inserm.fr). The titer was determined using dot blot and is expressed as vg per ml. 35 The vector titer was 1Â10 13 vg per ml. The vector batch was characterized using a modified replication center assay. 35 No infectious adenovirus or rep-positive AAV was detected.
The efficacy of gene transfer in mouse cornea was first assessed using AAV-CMV-GFP (AAV2/8.gfp). 36 Corneal expression of AAV2/8.mmp14 was assessed using two methods: reverse transcriptase PCR with primers specifically recognizing rMMP14 (F: 5¢-CGGGCGGATCCACCAT-3¢, R: 5¢-GCCAGGCTTCG GGGCT-3¢) and primers recognizing both rMMP14 and MMP14 (MMP14 see reverse transcriptase-real time PCR section) to evaluate the overall change in MMP14 expression. An evaluation was performed at D7 and D14 after the injection for rMMP14. Non-injected corneas were used as a control for MMP14 mRNA. Expression levels were normalized as a ratio of the expression level of housekeeping genes.
Immunofluorescence was performed with anti-MMP14 mouse monoclonal antibody (clone VMA3317, AbCys S.A, Paris, France) as described in the immunochemistry section.
Stromal cornea delivery
Before the intracorneal injection, a single drop of 0.4% oxybuprocaine (Novartis Pharma Schweiz AG) was administered to the eye. The eye was fixed with a fine-toothed forceps and the 10 ml vector solution (vector, fluorescein 0.005%, PBS) was injected using a sterile gas-tight microliter syringe (Hamilton Company, Reno, NV, USA) and a 33-gauge needle (Hamilton Company), after a Beaver blade (BD sclerotome multi-sided blade, Franklin Lakes, NJ, USA) was used to enter the superficial stroma. The injection was made at the superior side, one-third off center, and was considered successful if a circular opacity centered on the corneal apex was formed during the injection. When this bleb extended across 3/4 of the surface of the cornea, no additional solution was injected and the needle was carefully removed. The bleb was visible for only a few hours. Perforation occurred occasionally; these eyes were excluded from evaluation. The inoculated animals were examined regularly by slit-lamp biomicroscopy. Mice were euthanized at various time points.
For the murine full-thickness incision assay, AAV was injected 10 h before the full-thickness incision.
Immunohistochemistry
The a-SMA expression was visualized using a Dako ARK peroxidase kit (K3954, Dako, Glostrup, Denmark). Corneal cross-sections of 3 mm thick were cut, deparaffinized and rehydrated in PBS.
MMP14 staining was performed with a mouse monoclonal anti-MMP14 antibody (clone VM13317, Abcys, Paris, France). Corneal cross-sections of 3 mm thick were cut, deparaffinized and rehydrated in PBS. Image-it Fx signal enhancer (Invitrogen, Carlsbad, CA, USA) was applied for 30 min. The sections were then rinsed twice with PBS, 0.3% bovine serum albumin and incubated with primary mouse monoclonal anti-MMP14 antibody (1:100) for 1 h. Following washing, the sections were incubated for 1 h with Alexa fluor 488 antibody goat antimouse (1:200, Invitrogen), washed twice and incubated with Prolong Gold anti-fade reagent (Invitrogen).
Reverse transcriptase-real time PCR
